Pacira Biosciences, Inc. insider trading
Every open-market purchase and sale by Pacira Biosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Pacira Biosciences, Inc.’s insiders pay?
From February 10, 2011 to March 19, 2026, 36 insiders reported 30 open-market purchases and 117 sales not made under a pre-set plan in Pacira Biosciences, Inc. Twelve months after each purchase was reported, the shares were +32.1% against the S&P 500 on average (median +49.3%), over 30 purchases with a full year of prices; 57% beat the index. After sales, the shares moved +4.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 11, 2011 into $267,107 by November 2, 2026, +23.3% a year. It held shares 62% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $36,814 (+8.7% a year), and held throughout $74,870 (+13.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Riker Lauren | Senior Vice President, Finance | 0 | — | — | 22 | −7.3% (22) | June 5, 2025 |
| Wicki Andreas | Director | 1 | +101.6% (1) | 100% | 18 | +24.1% (18) | March 16, 2021 |
| Pace Gary W | Director | 5 | +37.3% (5) | 40% | 3 | −41.8% (3) | March 8, 2024 |
| Williams Kristen | Chief Administrative Officer | 0 | — | — | 8 | −17.1% (8) | June 5, 2025 |
| Hastings Paul J | Director | 1 | +155.0% (1) | 100% | 5 | −9.6% (5) | June 7, 2023 |
| Mcloughlin Dennis | Chief Customer Officer | 0 | — | — | 6 | −16.2% (6) | June 7, 2023 |
| Reinhart Charles A. III | Chief Financial Officer | 0 | — | — | 6 | −15.9% (6) | June 7, 2023 |
| Winston Roy | Chief Medical Officer | 1 | +56.6% (1) | 100% | 5 | −31.6% (5) | August 4, 2023 |
| Evnin Luke | Director | 2 | +74.9% (2) | 100% | 3 | +138.6% (3) | May 8, 2013 |
| Kronenfeld Mark A. | Director | 5 | +13.4% (5) | 40% | 0 | — | March 8, 2019 |
| Stack David M | CEO and Chairman | 0 | — | — | 5 | −18.7% (5) | June 7, 2023 |
| Froimson Mark | Director | 1 | +79.7% (1) | 100% | 3 | −23.1% (2) | March 19, 2026 |
| Jones James B | SVP & Chief Medical Officer | 2 | −62.1% (2) | 0% | 2 | −13.5% (2) | November 20, 2017 |
| Longenecker John P Phd | Director | 1 | −64.4% (1) | 0% | 3 | −12.2% (3) | March 7, 2022 |
| Slonin Jonathan | Chief Clinical Officer | 0 | — | — | 4 | −47.4% (4) | June 7, 2023 |
| Bigal Marcelo | Director | 2 | +74.4% (2) | 100% | 1 | −28.9% (1) | August 11, 2025 |
| Brege Laura | Director | 1 | +69.1% (1) | 100% | 2 | −26.2% (2) | August 19, 2024 |
| Isaly Samuel D | 10% owner | 0 | — | — | 3 | +105.2% (3) | March 13, 2012 |
| Laranjeira Charles Anthony | Chief Technical Officer | 0 | — | — | 3 | −4.0% (3) | June 8, 2021 |
| Pratt John | General Manager, San Diego | 0 | — | — | 3 | +144.9% (3) | June 14, 2013 |
| Scibetta James S | President | 2 | +0.8% (2) | 50% | 1 | −32.7% (1) | June 7, 2017 |
| Braunstein Scott | SVP, Strategy & Corp. Dev. | 1 | −56.6% (1) | 0% | 1 | −32.7% (1) | June 7, 2017 |
| Manning Donald C. | Chief Medical Officer | 0 | — | — | 2 | −0.7% (2) | June 10, 2021 |
| Ellis Ronald J. JR. | Chief Strategy Officer | 0 | — | — | 1 | −48.7% (1) | June 7, 2023 |
| Gaugler Daryl | Chief Operating Officer | 0 | — | — | 1 | −46.4% (1) | June 8, 2022 |
| Lee Frank D. | Chief Executive Officer | 1 | +79.8% (1) | 100% | 0 | — | August 13, 2024 |
| Markvicka Taunia | SVP, Chief Commercial Officer | 1 | −37.9% (1) | 0% | 0 | — | November 12, 2014 |
| Middleton Fred A | Director | 1 | +112.6% (1) | 100% | 0 | — | November 23, 2011 |
| Orbimed Capital Gp III LLC | 10% owner | 0 | — | — | 1 | +121.5% (1) | February 29, 2012 |
| Reinhardt Max | President, Rest of World | 0 | — | — | 1 | −48.7% (1) | June 7, 2023 |
| Sanderling Venture Partners VI Co Investment Fund LP | 10% owner | 0 | — | — | 1 | +201.7% (1) | January 25, 2013 |
| Sanderling Venture Partners VI LP | 10% owner | 0 | — | — | 1 | +125.9% (1) | March 11, 2013 |
| Scranton Richard | Chief Scientific Officer | 0 | — | — | 1 | +11.9% (1) | June 6, 2018 |
| Weiland Robert J. | Chief Commercial Officer | 0 | — | — | 1 | +11.9% (1) | June 6, 2018 |
| Winger Dennis L | Director | 1 | −34.4% (1) | 0% | 0 | — | December 8, 2014 |
| Yang Michael J. | Director | 1 | +71.6% (1) | 100% | 0 | — | August 14, 2024 |
When several insiders traded Pacira Biosciences, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Pacira Biosciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 5 buying crowds with six months of prices, it averaged +9.2% against the index. After 10 selling crowds, −0.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 29, 2025 | 3 selling | −17.9% | −23.2% | −20.2% |
| August 30, 2024 | 5 buying | +1.5% | +47.0% | +55.2% |
| June 30, 2023 | 11 selling | −20.2% | −23.8% | −68.8% |
| March 31, 2022 | 3 selling | −9.0% | −10.1% | −38.3% |
| March 31, 2021 | 5 selling | −21.8% | −29.4% | −9.3% |
| June 30, 2020 | 8 selling | +5.0% | −8.7% | −25.2% |
| December 31, 2019 | 3 selling | −5.8% | +19.8% | +11.9% |
| June 28, 2019 | 7 selling | −9.3% | −8.7% | +13.6% |
| June 29, 2018 | 6 selling | +45.7% | +41.1% | +21.3% |
| June 30, 2017 | 6 selling | −25.7% | −15.8% | −45.7% |
| January 29, 2016 | 2 buying | −16.0% | −52.2% | −58.6% |
| November 28, 2014 | 2 buying | −2.4% | −19.6% | −33.8% |